- In September 2023, Medicines360, a rare nonprofit pharma, spent $82 million to bring a $50 hormonal IUD, Liletta, to market. Despite hurdles like FDA regulations, funding challenges, and market resistance, it expanded access for low-income women, saving the U.S. healthcare system $100 million and sparking ongoing legislative efforts for nonprofit drug development.
- https://toronto.citynews.ca/2023/09/01/medicines360s-long-and-winding-82-million-road-to-create-and-distribute-50-birth-control/
- In January 2024, Medicines360, a nonprofit women’s health pharmaceutical organization, in partnership with Theramex, announced the commercial launch of LILETTA® (levonorgestrel-releasing intrauterine system) in Canada. This milestone expands access to long-acting reversible contraceptives (LARCs) for Canadian women, aligning with public health efforts to improve reproductive health options and equity.
